Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan S Coates

Showing results (21-30 of 106) with videos related to

Pageof 11
Sort By:
Breast Cancer Research and Treatment|March 3, 2010
Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancerRobert J Paridaens, Shari Gelber, Bernard F Cole, et al.
Cancer|December 22, 2005
Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trialsLorenzo Gianni, Ilaria Panzini, Sigui Li, et al.
Breast Cancer Research and Treatment|February 4, 2010
Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancersIsabella Castellano, Elena Allia, Valeria Accortanzo, et al.
Breast Cancer Research and Treatment|March 13, 2009
Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapyEugenio Maiorano, Meredith M Regan, Giuseppe Viale, et al.
Psycho-Oncology|July 21, 2006
Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancerVlatka M Duric, Phyllis N Butow, Louise Sharpe, et al.
Springerplus|September 12, 2013
Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisoneChee Khoon Lee, Val J Gebski, Alan S Coates, et al.
Patient Education and Counseling|April 25, 2008
Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancerVlatka M Duric, Phyllis N Butow, Louise Sharpe, et al.
Breast Cancer Research and Treatment|February 9, 2008
Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93Beat Thürlimann, Karen N Price, Richard D Gelber, et al.
European Journal of Cancer (Oxford, England : 1990)|December 9, 2008
Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study GroupLorenzo Gianni, Shari Gelber, Alberto Ravaioli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2003
Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IVDiana Crivellari, Karen Price, Richard D Gelber, et al.
Pageof 11

Showing results (21-30 of 106) with videos related to

Sort By:
Pageof 11
Breast Cancer Research and Treatment|March 3, 2010
Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancerRobert J Paridaens, Shari Gelber, Bernard F Cole, et al.
Cancer|December 22, 2005
Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trialsLorenzo Gianni, Ilaria Panzini, Sigui Li, et al.
Breast Cancer Research and Treatment|February 4, 2010
Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancersIsabella Castellano, Elena Allia, Valeria Accortanzo, et al.
Breast Cancer Research and Treatment|March 13, 2009
Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapyEugenio Maiorano, Meredith M Regan, Giuseppe Viale, et al.
Psycho-Oncology|July 21, 2006
Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancerVlatka M Duric, Phyllis N Butow, Louise Sharpe, et al.
Springerplus|September 12, 2013
Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisoneChee Khoon Lee, Val J Gebski, Alan S Coates, et al.
Patient Education and Counseling|April 25, 2008
Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancerVlatka M Duric, Phyllis N Butow, Louise Sharpe, et al.
Breast Cancer Research and Treatment|February 9, 2008
Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93Beat Thürlimann, Karen N Price, Richard D Gelber, et al.
European Journal of Cancer (Oxford, England : 1990)|December 9, 2008
Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study GroupLorenzo Gianni, Shari Gelber, Alberto Ravaioli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2003
Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IVDiana Crivellari, Karen Price, Richard D Gelber, et al.
Pageof 11